PARAGON-HF: Sacubitril/Valsartan vs Valsartan in Patients With and Without Diabetes and Heart Failure With Preserved Ejection Fraction

April 2-4, 2022; Washington, DC
In patients with HFpEF, sacubitril/valsartan attenuated the rate of decline in renal outcomes similarly in patients with and without diabetes compared to valsartan alone.
Format: Microsoft PowerPoint (.ppt)
File Size: 214 KB
Released: April 6, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck Sharp & Dohme Corp.

Related Content

Clinical Care Options (CCO) and Practicing Clinicians Exchange (PCE) ClinicalThought commentary with answers from expert faculty on frequently asked questions on SDOH in NVAF

Keith C. Ferdinand, MD, FACC, FAHA
Program Director
David S. Kountz, MD Laura Ross, PA-C, CLS
Released: May 26, 2022

Expert commentary on updates to the 2022 AHA/ACC/HFSA heart failure guidelines, from Clinical Care Options (CCO)

Lee R. Goldberg, MD, MPH, FACC Physicians: maximum of 0.5 AMA PRA Category 1 Credits Released: May 10, 2022 Expired: May 9, 2023

Clinical Care Options (CCO): Expert commentary covering new data in HFpEF diagnosis and treatment from ACC 2022 Annual Scientific Sessions

Lee R. Goldberg, MD, MPH, FACC Physicians: maximum of 0.5 AMA PRA Category 1 Credits Released: April 26, 2022 Expired: April 25, 2023

Clinical Care Options (CCO): Expert commentary covering new data in HFrEF management from ACC 2022, including SODIUM-HF, PROMPT-HF, DIAMOND, and EMPULSE

Lee R. Goldberg, MD, MPH, FACC Physicians: maximum of 0.5 AMA PRA Category 1 Credits Released: April 20, 2022 Expired: April 19, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings